Bayer Narrows Q3 Loss and Raises Full-Year Guidance

what happened

Bayer reported a third-quarter 2026 net loss attributable to shareholders of 672 million euros, down from 963 million euros a year earlier. Loss per share narrowed to 0.69 euros from 0.98 euros.

Group EBITDA before special items rose 6.9% to 1.615 billion euros. Core net income from continuing operations fell to 304 million euros from 480 million euros, and core earnings per share dropped to 0.31 euros from 0.49 euros. Group sales reached 10.05 billion euros, up 4.1% as reported and 1.9% after currency and portfolio adjustments.

Because performance in the first nine months beat expectations, the company raised its guidance. The EBITDA margin before special items for the Pharmaceuticals Division is now expected at 25% to 27%, up from 23% to 25%. Group EBITDA before special items is seen at 9.8 billion to 10.3 billion euros on a currency-adjusted basis, compared with the earlier 9.6 billion to 10.1 billion euros. Bayer shares closed at 50.02 euros on Xetra.

why it matters

The key signal for markets is the higher outlook despite a sharp drop in core earnings per share during the quarter. The pharmaceuticals segment carried the results, and investors will watch whether margin gains hold in the coming quarters.

market impact

Акции Bayer: повышение прогноза и меньший убыток поддерживают бумаги компании

• ▲Bayer shares pressure up — raised guidance and a narrower net loss support sentiment toward the stock

tags

instruments